| ALK

Privacy values statement

ALK Privacy Values Statement

1. Respecting Privacy. In ALK, we respect the privacy and the rights of individuals in all areas of our business.
 
2. Individual rights, adequate information and access. Individuals need to be adequately informed about the processing of their personal data, their rights, and be allowed to access such data.
 
3. Care and diligence when handling requests and complaints. Any requests or complaints made by the individuals need to be handled with care and diligence.
 
4. Being fair and just in what we do. Processing of personal data not only needs to be legal, it also needs to be fair in the given circumstances and we need to be open about such practices.
 
5. Clearly defined purposes. Personal data may only be collected and used for clearly defined purposes.
 
6. Reasonable scope. The least amount of data sufficient for the given purposes must be collected, used and retained.
 
7. Quality of data is important. High quality/accuracy of data must be maintained and, as soon as no longer needed, data need to be deleted.
 
8. Reasonable protection. Personal data require reasonable protection and must be treated as confidential.
 
9. Life-cycle perspective. Full life-cycle protection, including transfers, need to be maintained.
 
10. Privacy is part of our DNA. Data protection should be embedded in the core settings and design of every product, process or service and not treated as an afterthought.
 
11. Sensitive data. Sensitive data merit special protection.
 
12. Special care in using technology in the decision-making process. Profiling and automated decision-making require very careful analysis before being allowed to be implemented.
 
13. International transfers. International transfers of personal data may be subject to specific requirements and limitations.
 
14. Privacy follows the data. Both internal and external transfers of personal data may be needed for our business operations, but the personal data must still be adequately protected.
 
15. Privacy standards when using third party processors. Entities processing data on our behalf must meet sufficient standards and appropriate contracts need to be in place.
 
16. Keeping track of what we do to protect your privacy. Our compliance efforts must be documented, so we can demonstrate where we stand on privacy.
 
17. Privacy is our joint responsibility. To protect personal data all departments and affiliates need to cooperate.
 
18. Being serious about possible breaches. Any breach must be reported immediately.
 
19. Keeping adequate records. Sufficient records of our operations must be kept. 
 
20. Compliance program. Audits, reviews, and assessments are required to ensure that a high level of data protection is being met.
 
21. Training and awareness. ALK staff processing personal data must be adequately trained.
 
22. Reporting misconducts. Reasonable efforts to prevent any breaches need to be taken and misconducts reported.
Last updated: 12.01.2024

Review of application

Review of application

Access to data may be provided following review of the application by a scientific review board including independent academic scientists and healthcare professionals.

The members of the scientific review board are:

The review process and role of the independent scientific review board is described in the scientific review board charter. Review criteria include general assessment, the patient’s perspective, a scientific perspective and a methodology assessment.

If access to data is granted, you will be given an estimated timeline for data sharing. An independent third party will analyse the data according to the statistical analysis plan and forward the results directly to you.

Applicants must publish the results as stated in the submitted publication plan.

Last updated: 12.01.2024

How to apply

Last updated: 12.01.2024

The Henning Løwenstein Research Award

Last updated: 25.11.2021

Cultural Beliefs

Our Cultural Beliefs

Do the right thing Pursue growth Build bridges

Last updated: 08.07.2019

Working at ALK

Meet our people

Working at ALK

Last updated: 09.11.2016

Privacy

Get answers about privacy

ALK Privacy

We have recently added some further detail in our Privacy Statement, making it easier for you to understand what data we collect, how we use it and your rights to manage that information.
Last updated: 18.05.2018

COVID-19 webinars

Last updated: 04.06.2021

Healthcare Professionals

Explore more information about allergy immunotherapy (AIT) and its long-term disease-modifying and protective effects, ALK’s movement from experience- to evidence-based AIT with clinical trials and real-world evidence, and our compliance with guidelines and sharing of clinical data. All collected for you as a healthcare professional with the purpose of improving the understanding of allergic disease, assisting prescriber decisions, and helping more people living with allergy.

We also present The Henning Løwenstein Research Award – an award to young scientists who has shown excellence within the field of allergy. 

Finally, you can read more about our work with a new allergy portal for healthcare proffesionals here.

Avatar

Allergy immunotherapy

AIT is the only treatment targeting the root cause of allergy – the immune system. Therefore, AIT has not only the capacity of improving symptoms and reducing the need for other medication, but also to induce specific tolerance beyond the duration of treatment, modify the course of the disease, and prevent development of new sensitisations and co-morbidities.

Avatar

Our data

In ALK, we focus on expanding the access to evidence-based AIT. We commit to investigating the safety and efficacy of specific treatment in controlled settings – clinical trials – and in uncontrolled settings – the real-world. This commitment offers the best of two worlds, assisting prescribers in treatment decisions and thereby helping people living with allergy.

Avatar

Henning Løwenstein Research Award

The Henning Løwenstein Research Award was established and dedicated to researcher Henning Løwenstein by ALK on his 25th anniversary of work at the company. This biennial award is given to a young scientist who has shown excellence within the field of allergy research.

New allergy portal for healthcare professionals

We are currently building a new portal for healthcare professionals, granting access to comprehensive educational resources and clinical support within the most common respiratory allergies. This will be launched in 2025 and continuously expanded with the latest medical information. Please keep posted.

In the meantime, you as a healthcare professional are welcome to register as a user and get access to The Henning Løwenstein Research Award ceremonies of 2024 and 2021 as well as educational and clinical webinars with medical experts' perspectives and panel discussions within the field of respiratory allergy.

Thank you for your patience.


Henning Løwenstein Research Award ceremonies

Watch the 2024 and 2021 Henning Løwenstein Research Award ceremonies including lectures by the winners Kelly Bruton (2024) and Julia Esser-von Bieren (2021) as well as list of previous ceremonies and winners of the award.


Medical events

Get access to interactive educational and clinical webinars in which medical experts within the field of respiratory allergy share their perspectives and discuss AIT, management of patients with respiratory allergies, and clinical practices.

Last updated: 12.12.2024

Allergy immunotherapy

Healthcare professionals

Allergy immunotherapy

Targets the root cause of allergy by stimulating an immune response

Allergy immunotherapy (AIT) is the only treatment of allergic disease that addresses the underlying cause of the disease: the immune system. Therefore, it is also the only treatment capable of modifying the course of the disease.

It works by administering repeated doses of the specific allergen that the patient is allergic to. This stimulates an immune response in the body, which causes the patient to build up immunological tolerance against the given allergen. 

AIT is proven not only to improve the patient’s symptoms and need for symptom-relieving medication, but also to induce specific tolerance beyond the duration of the treatment. By targeting the specific allergen that triggers a patient’s symptoms, AIT inhibits the occurrence of both seasonal and perennial allergic reactions. 

Disease-modifying and protective effect

To achieve long-term sustained effect, where the benefits of the treatment continue after the treatment has ended, it is recommended to treat with AIT for three to five years. Because of the induced immunological tolerance, AIT not only provides long-term relief of symptoms and improvement of quality of life, but also has the potential of preventing onset of new sensitisations, allergic conditions, and progression into asthma as well as impacting asthma severity. Neither of these disease-modifying and protective effects are possible with symptom-relieving medication. 

Why has AIT disease-modifying effect?

References
  • Alvaro-Lozano M et al. EAACI Allergen Immunotherapy User's Guide. Pediatr Allergy Immunol. 2020;31 Suppl 25(Suppl 25):1-101
  • Durham SR et al. J Allergy Clin Immunol. 2012;129(5):717-725; 2
  • Global Atlas of Allergy, EAACI 2014
  • Larsen JN et al. Drug Discov Today 2016:21(1):26-37
  • Penagos M, Durham S. Long-term efficacy of the sublingual and subcutaneous routes in allergen immunotherapy. Allergy Asthma Proc 202243(4):292-298
  • Shamji MH et al. J Allergy Clin Immunol 2017;140(6):1485-1498
  • Valovirta E et al. J Allergy Clin Immunol. 2018;141(2):529-38
Last updated: 17.12.2024